What do systematic reviews say?

Honey vs salbutamol

Honey showed no clear difference in rash compared with salbutamol (moderate certainty).

• Honey for acute cough in children 2018 · Cochrane Headline outcomes only
  RR 0.19 [0.02, 1.63]
  1 study · 100 participants
  Moderate

Honey vs salbutamol

Honey showed no clear difference in tachycardia compared with salbutamol (low certainty).

• Honey for acute cough in children 2018 · Cochrane Headline outcomes only
  RR 1.51 [0.14, 16.1]
  1 study · 100 participants
  Low

Honey vs salbutamol

Honey showed no clear difference in diarrhoea compared with salbutamol (moderate certainty).

• Honey for acute cough in children 2018 · Cochrane Headline outcomes only
  RR 0.59 [0.24, 1.45]
  1 study · 100 participants
  Moderate

Epinephrine vs salbutamol/albuterol

Epinephrine showed no clear difference in admissions at enrollment or < 24 hours (outpatients only) compared with salbutamol/albuterol (moderate certainty).

• Epinephrine for bronchiolitis 2011 · Cochrane Headline outcomes only
  RR 0.67 [0.41, 1.09]
  7 studies · 444 participants
  Moderate

Epinephrine vs salbutamol/albuterol

Epinephrine showed no clear difference in admissions overall up to 7 days (outpatients only) compared with salbutamol/albuterol (moderate certainty).

• Epinephrine for bronchiolitis 2011 · Cochrane Headline outcomes only
  RR 1.05 [0.71, 1.54]
  2 studies · 212 participants
  Moderate

Epinephrine vs salbutamol/albuterol

• Epinephrine for bronchiolitis 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 261 participants
  Moderate

Steam inhalation (mist) vs salbutamol

• Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 104 participants
  Moderate
• Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 104 participants
  Moderate

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with regular salbutamol (moderate certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 0.96 [0.85, 1.1]
  5 studies · 27002 participants
  Moderate

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with regular salbutamol (moderate certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 1.37 [0.71, 2.64]
  3 studies · 1181 participants
  Moderate

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in asthma‐related mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 2.36 [0.78, 7.16]
  4 studies · 26463 participants
  Moderate

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with regular salbutamol (low certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 0.94 [0.37, 2.34]
  3 studies · 1155 participants
  Low

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with regular salbutamol (low certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 1.04 [0.47, 2.31]
  3 studies · 1186 participants
  Low

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in all‐cause mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 1.28 [0.79, 2.05]
  4 studies · 26463 participants
  Moderate

Regular salmeterol vs salbutamol

Regular salmeterol showed no clear difference in all‐cause mortality ‐ children compared with regular salbutamol (low certainty).

• Regular treatment with salmeterol for chronic asthma: serious adverse events 2008 · Cochrane Headline outcomes only
  OR 0.04 [0, 2.97]
  3 studies · 1152 participants
  Low